NFE2L2 and neoplasm: It has also been confirmed in an in vivo xenograft tumor model that DSF/Cu restrains the progression of OSCC via curbing the expression of Nrf2/HO-1, thereby presenting a novel approach for treating OSCC [21] (Fig. 2).